Christoph Helwig
About
Christoph Helwig is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine.
According to data from OpenAlex, Christoph Helwig has authored 53 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 44 papers in Oncology, 16 papers in Molecular Biology and 16 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Christoph Helwig's work include Pancreatic and Hepatic Oncology Research (18 papers), Cancer Immunotherapy and Biomarkers (17 papers) and Cancer Research and Treatments (14 papers). Christoph Helwig is often cited by papers focused on Pancreatic and Hepatic Oncology Research (18 papers), Cancer Immunotherapy and Biomarkers (17 papers) and Cancer Research and Treatments (14 papers). Christoph Helwig collaborates with scholars based in Germany, United States and South Korea. Christoph Helwig's co-authors include James L. Gulley, Lisa Mahnke, Isabelle Dussault, Laureen S. Ojalvo, Julius Strauss, Elizabeth Lamping, Jennifer L. Marté, Jeffrey Schlom, Ravi A. Madan and Lisa M. Cordes and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.
In The Last Decade
Christoph Helwig
53 papers receiving 1.4k citations
Hit Papers
Peers
Christoph Helwig
Raid Aljumaily United States
Jean-Marie Cuillerot United States
Suroosh S. Marzban United States
Franz O. Smith United States
Christopher A. Puleo United States
Lisa M. Cordes United States
Rodrigo Ramella Munhoz Brazil
Boel Ragnarsson-Olding Sweden
Jean-Marie Cuillerot United States
Darya Buehler United States
Citations per year, relative to Christoph Helwig Christoph Helwig (= 1×)
peers
Raid Aljumaily
Countries citing papers authored by Christoph Helwig
Since
Specialization
Citations
This map shows the geographic impact of Christoph Helwig's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christoph Helwig with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christoph Helwig more than expected).
Fields of papers citing papers by Christoph Helwig
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Christoph Helwig. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christoph Helwig. The network helps show where Christoph Helwig may publish in the future.
Co-authorship network of co-authors of Christoph Helwig
This figure shows the co-authorship network connecting the top 25 collaborators of Christoph Helwig. A scholar is included among the top collaborators of Christoph Helwig based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christoph Helwig. Christoph Helwig is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Venetis, Christos, Christoph Helwig, Ben W. Mol, et al.. (2023). Correction: Biosimilar recombinant follitropin alfa preparations versus the reference product (Gonal-F®) in couples undergoing assisted reproductive technology treatment: a systematic review and meta-analysis. Reproductive Biology and Endocrinology. 21(1). 68–68.
2.
Barlési, Fabrice, Nicolás Isambert, Enriqueta Felip, et al.. (2022). Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients with Non-Small Cell Lung Cancer Resistant or Refractory to Immune Checkpoint Inhibitors. The Oncologist. 28(3). 258–267.
3.
Khasraw, Mustafa, Michael Weller, David Lorente, et al.. (2021). Bintrafusp alfa (M7824), a bifunctional fusion protein targeting TGF-β and PD-L1: results from a phase I expansion cohort in patients with recurrent glioblastoma. Neuro-Oncology Advances. 3(1). vdab058–vdab058.
4.
Lin, Chia‐Chi, Toshihiko Doi, Kei Muro, et al.. (2021). Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGFβ and PD-L1, in Patients with Esophageal Squamous Cell Carcinoma: Results from a Phase 1 Cohort in Asia. Targeted Oncology. 16(4). 447–459.
5.
Gulley, James L., Mario E. Lacouture, Alexander I. Spira, et al.. (2021). 1689P Adverse event management during treatment with bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1: Treatment guidelines based on experience in clinical trials. Annals of Oncology. 32. S1181–S1182.
6.
Tan, Benjamin, Adnan Khattak, Enriqueta Felip, et al.. (2021). Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients with Esophageal Adenocarcinoma: Results from a Phase 1 Cohort. Targeted Oncology. 16(4). 435–446.
7.
Oh, Do‐Youn, Filippo de Braud, John Bridgewater, et al.. (2021). P5-5 Phase 2/3 study of bintrafusp alfa with gemcitabine plus cisplatin as first-line treatment of biliary tract cancer. Annals of Oncology. 32. S333–S333.
8.
Rolfo, Christian, Laurent Greillier, Rémi Veillon, et al.. (2021). 465 Bintrafusp alfa in combination with chemotherapy in patients with stage IV NSCLC: safety and pharmacokinetic results of the INTR@PID LUNG 024 study. SHILAP Revista de lepidopterología. A494–A494.
9.
Kang, Yoon‐Koo, Yung‐Jue Bang, Shunsuke Kondo, et al.. (2020). Safety and Tolerability of Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGFβ and PD-L1, in Asian Patients with Pretreated Recurrent or Refractory Gastric Cancer. Clinical Cancer Research. 26(13). 3202–3210.
10.
Cho, Byoung Chul, Amaury Daste, Alain Ravaud, et al.. (2020). Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort. Journal for ImmunoTherapy of Cancer. 8(2). e000664–e000664.
11.
Oh, D-Y., Filippo de Braud, John Bridgewater, et al.. (2020). 79TiP A phase II/III, randomized, placebo-controlled study of bintrafusp alfa with gemcitabine plus cisplatin as first-line treatment of biliary tract cancer. Annals of Oncology. 31. S271–S272.
12.
Paz‐Ares, Luis, David Vicente, Enriqueta Felip, et al.. (2020). 1272P Three-year follow-up of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, for second-line (2L) treatment of non-small cell lung cancer (NSCLC). Annals of Oncology. 31. S822–S822.
13.
Paz‐Ares, Luis, Tae Min Kim, David Vicente, et al.. (2020). Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial. Journal of Thoracic Oncology. 15(7). 1210–1222.
14.
Strauss, Julius, Christopher R. Heery, Jeffrey Schlom, et al.. (2018). Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors. Clinical Cancer Research. 24(6). 1287–1295.
15.
Bang, Yung‐Jue, Toshihiko Doi, Shunsuke Kondo, et al.. (2018). Updated results from a phase I trial of M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients with pretreated recurrent or refractory gastric cancer. Annals of Oncology. 29. viii222–viii223.
16.
Yoo, Changhoon, Do‐Youn Oh, Hye Jin Choi, et al.. (2018). M7824 (MSB0011359C), a bifunctional fusion protein targeting transforming growth factor β (TGF-β) and PD-L1, in Asian patients with pretreated biliary tract cancer (BTC): Efficacy by BTC subtype. Annals of Oncology. 29. ix48–ix49.
17.
Katakami, Nobuyuki, Toyoaki Hida, Hiroshi Nokihara, et al.. (2017). Phase I/II study of tecemotide as immunotherapy in Japanese patients with unresectable stage III non-small cell lung cancer. Lung Cancer. 105. 23–30.
18.
Becker, Jan U., et al.. (2016). Evaluation of real world treatment outcomes in patients with metastatic merkel cell carcinoma (MCC) following second line chemotherapy. Annals of Oncology. 27. vi397–vi397.
19.
Cowey, C. Lance, Lisa Mahnke, Janet L. Espirito, et al.. (2016). Real-World Outcomes of Patients with Metastatic Merkel Cell Carcinoma Treated with Second-Line or Later Chemotherapy in A Community Oncology Setting in The United States. Value in Health. 19(7). A717–A717.
20.
Mitchell, Paul, N. Thatcher, Mark A. Socinski, et al.. (2015). Tecemotide in unresectable stage III non-small-cell lung cancer in the phase III START study: updated overall survival and biomarker analyses. Annals of Oncology. 26(6). 1134–1142.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Raid Aljumaily Breakdown of academic impact, for papers by Jean-Marie Cuillerot Breakdown of academic impact, for papers by Suroosh S. Marzban Breakdown of academic impact, for papers by Franz O. Smith Breakdown of academic impact, for papers by Christopher A. Puleo Breakdown of academic impact, for papers by Lisa M. Cordes Breakdown of academic impact, for papers by Rodrigo Ramella Munhoz Breakdown of academic impact, for papers by Boel Ragnarsson-Olding Breakdown of academic impact, for papers by Jean-Marie Cuillerot Breakdown of academic impact, for papers by Darya Buehler